Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) , an approach developed by Dr. Leigh Anderson , is a novel technology that  can achieve high sensitivity quantitation of proteins in clinical samples using  affinity - capture  SRM Mass spectrometry. One of the most desirable aspects of SISCAPA technology is that it h as the potential for simultaneous quantification of multiple  proteins from a given sample making it is highly desirable in  many applications to minimize sample requirements, handling, and assay costs per analyte . However, the capabilities of the SISCAPA technique are currently limited due to the scarcity of high  affinity antibodies to the specific peptides that are generated by the fragmentation  of the target  protein before analysis.  

Producing high quality antibodies for SISCAPA assays fits well with OriGene's long term goal  of developing perfect assays for every human protein. The development of these  antibodies is being performed  in  partnership with the Institute for Systems Biology (ISB) and in  coordination with NCI's Clinical Proteomic Technologies for Cancer (CPTC) group. OriGene has previously collaborated with Dr. Robert Moritz , Director of Proteomics Research at ISB , for the generation  of mass spec peptide profiles from over 5000  full length  human proteins for inclusion in the complete human SRMAtlas . For the generation of high - affinity SISCAPA antibodies under this contract, OriGene will utilize a novel immunization  strategy to develop high antibody titers in rabbits and will utilize the  proteomics capabilities of the Moritz lab to identify , isolate and characterize the highest affinity antibodies suitable for SISCAP A approaches . 

Dr. James Lazar, Vice President of Assay Development said, “OriGene is pleased to have been selected by NCI to receive this contract and to work with Dr. Moritz , a leader in this field. We believe that OriGene’s unique expertise in antibody development  will enable the true potential of SISCAP A technology and contribute to the development of important clinical assays”. 

Dr. Moritz commented : “ This is a fantastic opportunity  where we continue our collaboration  with OriGene  and combin e our collective knowledge and expertise in antibody generation and  protein chemistry to provide  ‘digitized ’ antibodies for the NCI CPTC program at the NIH and  support the effort of shared resources .”